Measurement of Gelatinase B (MMP-9) in the Cerebrospinal Fluid of Patients With Vascular Dementia and Alzheimer Disease

Background and Purpose— Vascular causes of dementia are increasing in importance because of the aging of the population. Biological markers to distinguish patients with vascular dementia (VaD) from Alzheimer disease (AD) would be very useful. Because cerebrovascular disease increases expression of brain matrix metalloproteinases (MMPs) and tissue inhibitors to metalloproteinases (TIMPs), we hypothesized that MMPs would be elevated in the cerebrospinal fluid (CSF) of patients with VaD, but not in patients with AD. Methods— Fifteen patients with VaD were identified, including dementia caused by multiple infarcts and progressive dementia caused by disease of the small cerebral blood vessels. Patients were followed-up for 4 to 10 years to confirm the diagnosis. Thirty patients with AD were also studied. Patients had CSF collected at their initial evaluation. Gelatinase A (MMP-2) and gelatinase B (MMP-9) were quantified by gelatin-substrate zymography, and TIMPs were measured by reverse zymography. Control CSF was obtained from neurologically normal subjects. Results— MMP-9 levels were significantly elevated in the CSF of VaD patients compared either to those with AD (P < 0.0001) or to controls. MMP-2, TIMP-1, and TIMP-2 were similar in patient groups and controls. Conclusions— Patients with multiinfarct and small vessel VaD have elevated levels of MMP-9 in the CSF compared with AD and controls. Although CSF MMP-9 increases in other neurological conditions and is not specific for VaD, it could provide an additional biological marker for the separation of patients with VaD and AD.

[1]  R. Gutala,et al.  The use of real-time PCR analysis in a gene expression study of Alzheimer’s disease post-mortem brains , 2004, Journal of Neuroscience Methods.

[2]  R. Stackman,et al.  Prevention of age-related spatial memory deficits in a transgenic mouse model of Alzheimer's disease by chronic Ginkgo biloba treatment , 2003, Experimental Neurology.

[3]  J. Ryu,et al.  Amyloid beta peptide-induced corpus callosum damage and glial activation in vivo. , 2003, Neuroreport.

[4]  Norman Relkin,et al.  Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer’s disease , 2003, Neurochemistry International.

[5]  M. Mattson,et al.  Triple-Transgenic Model of Alzheimer's Disease with Plaques and Tangles Intracellular Aβ and Synaptic Dysfunction , 2003, Neuron.

[6]  C. Haass,et al.  Neurotoxic Mechanisms Caused by the Alzheimer's Disease-linked Swedish Amyloid Precursor Protein Mutation , 2003, Journal of Biological Chemistry.

[7]  M. Onufriev,et al.  Single intracerebroventricular administration of amyloid-beta (25–35) peptide induces impairment in short-term rather than long-term memory in rats , 2003, Brain Research Bulletin.

[8]  J. Loring,et al.  Selectively Reduced Expression of Synaptic Plasticity-Related Genes in Amyloid Precursor Protein + Presenilin-1 Transgenic Mice , 2003, The Journal of Neuroscience.

[9]  M. Staufenbiel,et al.  Regional brain cytochrome oxidase activity in β-amyloid precursor protein transgenic mice with the swedish mutation , 2003, Neuroscience.

[10]  S. Lorenzl,et al.  Tissue inhibitors of matrix metalloproteinases are elevated in cerebrospinal fluid of neurodegenerative diseases , 2003, Journal of the Neurological Sciences.

[11]  J. Trojanowski,et al.  Neuron‐specific age‐related decreases in dopamine receptor subtype mRNAs , 2003, The Journal of comparative neurology.

[12]  N. Patel,et al.  Proinflammatory and Vasoactive Effects of Aβ in the Cerebrovasculature , 2002, Annals of the New York Academy of Sciences.

[13]  M. Ball,et al.  Gene expression profiling of 12633 genes in Alzheimer hippocampal CA1: Transcription and neurotrophic factor down‐regulation and up‐regulation of apoptotic and pro‐inflammatory signaling , 2002, Journal of neuroscience research.

[14]  D. Selkoe.  Alzheimer's Disease Is a Synaptic Failure , 2002, Science.

[15]  E. Mufson,et al.  Gene Expression Profiles of Cholinergic Nucleus Basalis Neurons in Alzheimer's Disease , 2002, Neurochemical Research.

[16]  Jeffrey A. Johnson,et al.  Lack of Neurodegeneration in Transgenic Mice Overexpressing Mutant Amyloid Precursor Protein Is Associated with Increased Levels of Transthyretin and the Activation of Cell Survival Pathways , 2002, The Journal of Neuroscience.

[17]  J. Morley.  A fall is a major event in the life of an older person. , 2002, The journals of gerontology. Series A, Biological sciences and medical sciences.

[18]  D. Selkoe,et al.  The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics , 2002, Science.

[19]  George A. Carlson,et al.  The Relationship between Aβ and Memory in the Tg2576 Mouse Model of Alzheimer's Disease , 2002, The Journal of Neuroscience.

[20]  S. Dudoit,et al.  Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. , 2002, Nucleic acids research.

[21]  D. Geschwind,et al.  An evaluation of tyramide signal amplification and archived fixed and frozen tissue in microarray gene expression analysis. , 2002, Nucleic acids research.

[22]  J. Blass.  Brain metabolism and brain disease: Is metabolic deficiency the proximate cause of Alzheimer dementia? , 2001, Journal of neuroscience research.

[23]  J M Lee,et al.  A gene expression profile of Alzheimer's disease. , 2001, DNA and cell biology.

[24]  Lars Bertram,et al.  New Frontiers in Alzheimer's Disease Genetics , 2001, Neuron.

[25]  L. Kappos,et al.  Matrix metalloproteinases: multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis , 2001, Brain Research Reviews.

[26]  S. Davis,et al.  Generation of Aggregated β-Amyloid in the Rat Hippocampus Impairs Synaptic Transmission and Plasticity and Causes Memory Deficits , 2001, The Journal of Neuroscience.

[27]  V. Wee Yong,et al.  Metalloproteinases in biology and pathology of the nervous system , 2001, Nature Reviews Neuroscience.

[28]  Virginia M. Y. Lee,et al.  Increased Lipid Peroxidation Precedes Amyloid Plaque Formation in an Animal Model of Alzheimer Amyloidosis , 2001, The Journal of Neuroscience.

[29]  K Kosaka,et al.  Up-regulation of calcineurin Abeta mRNA in the Alzheimer's disease brain: assessment by cDNA microarray. , 2001, Biochemical and biophysical research communications.

[30]  M. Esiri,et al.  White Matter Damage Is Associated With Matrix Metalloproteinases in Vascular Dementia , 2001, Stroke.

[31]  C. Haass,et al.  Elevated vulnerability to oxidative stress‐induced cell death and activation of caspase‐3 by the Swedish amyloid precursor protein mutation , 2001, Journal of neuroscience research.

[32]  D. Selkoe.  Alzheimer's disease: genes, proteins, and therapy. , 2001, Physiological reviews.

[33]  R. Mandler,et al.  Matrix metalloproteinases and tissue inhibitors of metalloproteinases in cerebrospinal fluid differ in multiple sclerosis and Devic's neuromyelitis optica. , 2001, Brain : a journal of neurology.

[34]  G. Sobue,et al.  Gene expression profile in Alzheimer's brain screened by molecular indexing. , 2001, Brain research. Molecular brain research.

[35]  A. Czernik,et al.  Altered expression of a-type but not b-type synapsin isoform in the brain of patients at high risk for Alzheimer's disease assessed by DNA microarray technique , 2001, Neuroscience Letters.

[36]  Mikio Shoji,et al.  Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease , 2001, The Journal of Neuroscience.

[37]  L. Gwyther,et al.  Family issues in dementia: finding a new normal. , 2000, Neurologic clinics.

[38]  J. Wands,et al.  Mitochondrial DNA Damage as a Mechanism of Cell Loss in Alzheimer's Disease , 2000, Laboratory Investigation.

[39]  M. Ko,et al.  Genome-wide expression profiling of mid-gestation placenta and embryo using a 15,000 mouse developmental cDNA microarray. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[40]  J. Trojanowski,et al.  Expression profile of transcripts in Alzheimer's disease tangle‐bearing CA1 neurons , 2000, Annals of neurology.

[41]  J. Kaye,et al.  Dementia in Rural Primary Care Practices in Lake County, Oregon , 2000, Journal of geriatric psychiatry and neurology.

[42]  Kang Hu,et al.  High-Level Neuronal Expression of Aβ1–42 in Wild-Type Human Amyloid Protein Precursor Transgenic Mice: Synaptotoxicity without Plaque Formation , 2000, The Journal of Neuroscience.

[43]  A. Nunomura,et al.  Mitochondrial abnormalities in Alzheimer disease , 2000, Neurobiology of Aging.

[44]  Howard Fillit,et al.  Cost of Alzheimer's Disease and Related Dementia in Managed‐Medicare , 1999, Journal of the American Geriatrics Society.

[45]  L. Boise,et al.  Diagnosing dementia: perspectives of primary care physicians. , 1999, The Gerontologist.

[46]  S. Wagner,et al.  Amyloid production and deposition in mutant amyloid precursor protein and presenilin-1 yeast artificial chromosome transgenic mice , 1999, Nature Neuroscience.

[47]  H. Edelberg,et al.  Medication Management Capacity in Highly Functioning Community‐Living Older Adults: Detection of Early Deficits , 1999, Journal of the American Geriatrics Society.

[48]  B. Reisberg,et al.  Equilibrium and Limb Coordination in Mild Cognitive Impairment and Mild Alzheimer's Disease , 1999, Journal of the American Geriatrics Society.

[49]  M. Tinetti,et al.  Drugs and Falls in Older People: A Systematic Review and Meta‐analysis: II. Cardiac and Analgesic Drugs , 1999, Journal of the American Geriatrics Society.

[50]  M. Tinetti,et al.  Drugs and Falls in Older People: A Systematic Review and Meta‐analysis: I. Psychotropic Drugs , 1999, Journal of the American Geriatrics Society.

[51]  M. Mattson,et al.  Amyloid β-peptide induces apoptosis-related events in synapses and dendrites , 1998, Brain Research.

[52]  H. Chertkow,et al.  Prevalence of potentially reversible dementias and actual reversibility in a memory clinic cohort. , 1998, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[53]  M. Beal,et al.  Mitochondrial dysfunction in neurodegenerative diseases. , 1998, Biochimica et biophysica acta.

[54]  P. Coleman,et al.  Expression profiles of multiple genes in single neurons of Alzheimer's disease. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[55]  M. Tabaton,et al.  Amyloid‐β Deposition in Alzheimer Transgenic Mice Is Associated with Oxidative Stress , 1998, Journal of neurochemistry.

[56]  V Hachinski,et al.  The effect of different diagnostic criteria on the prevalence of dementia. , 1997, The New England journal of medicine.

[57]  M. Esiri,et al.  Neuropathological assessment of the lesions of significance in vascular dementia , 1997, Journal of neurology, neurosurgery, and psychiatry.

[58]  S H Ferris,et al.  Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. , 1997, JAMA.

[59]  D. Borchelt,et al.  Accelerated Amyloid Deposition in the Brains of Transgenic Mice Coexpressing Mutant Presenilin 1 and Amyloid Precursor Proteins , 1997, Neuron.

[60]  B. Hyman,et al.  APPSW Transgenic Mice Develop Age‐related Aβ Deposits and Neuropil Abnormalities, but no Neuronal Loss in CA1 , 1997, Journal of neuropathology and experimental neurology.

[61]  D. Price,et al.  Altered metabolism of familial Alzheimer's disease-linked amyloid precursor protein variants in yeast artificial chromosome transgenic mice. , 1997, Human molecular genetics.

[62]  J. Hainfeld,et al.  Binding of Amyloid β Protein to the 20 S Proteasome* , 1997, The Journal of Biological Chemistry.

[63]  J. Hardy,et al.  Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1 , 1996, Nature.

[64]  S. Younkin,et al.  Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice , 1996, Science.

[65]  E. Barrett-Connor,et al.  Weight Loss Precedes Dementia in Community‐Dwelling Older Adults , 1996, The journal of nutrition, health & aging.

[66]  W. Brooks,et al.  Proton magnetic resonance spectroscopy of vascular- and Alzheimer-type dementia. , 1996, Archives of neurology.

[67]  R Brookmeyer,et al.  Reliability of the Blessed Telephone Information-Memory-Concentration Test , 1995, Journal of geriatric psychiatry and neurology.

[68]  W M Tierney,et al.  Documentation and Evaluation of Cognitive Impairment in Elderly Primary Care Patients , 1995, Annals of Internal Medicine.

[69]  L. Mucke,et al.  Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein , 1995, Nature.

[70]  H. Feldman,et al.  Canadian Guidelines for the Development of Antidementia Therapies: a Conceptual Summary , 1995, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[71]  L. Rubenstein,et al.  Inappropriate medication use in community-residing older persons. , 1994, Archives of internal medicine.

[72]  W. Stetler-Stevenson,et al.  Quantitative zymography: detection of picogram quantities of gelatinases. , 1994, Analytical biochemistry.

[73]  N. Butters,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part V. A normative study of the neuropsychological battery , 1994, Neurology.

[74]  D L Patrick,et al.  Screening for depression in well older adults: evaluation of a short form of the CES-D (Center for Epidemiologic Studies Depression Scale). , 1994, American journal of preventive medicine.

[75]  J. Blass.  Metabolic alterations common to neural and non‐neural cells in alzheimer's disease , 1993, Hippocampus.

[76]  J. Stevens,et al.  Applied Multivariate Statistics for the Social Sciences , 1993 .

[77]  W. Jagust,et al.  Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers , 1992, Neurology.

[78]  K. Blennow,et al.  Blood brain barrier function in vascular dementia , 1990, Acta neurologica Scandinavica.

[79]  J. Morris,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assesment of Alzheimer's disease , 1989, Neurology.

[80]  A M Clarfield,et al.  The reversible dementias: do they reverse? , 1988, Annals of internal medicine.

[81]  E. Larson,et al.  Excess Disability in Demented Elderly Outpatients: The Rule of Halves , 1988, Journal of the American Geriatrics Society.

[82]  Sydney Katz.  Assessing Self‐maintenance: Activities of Daily Living, Mobility, and Instrumental Activities of Daily Living , 1983, Journal of the American Geriatrics Society.

[83]  R. Katzman.,et al.  Validation of a short Orientation-Memory-Concentration Test of cognitive impairment. , 1983, The American journal of psychiatry.

[84]  L. Caplan,et al.  Clinical features of subcortical arteriosclerotic encephalopathy (Binswanger disease) , 1978, Neurology.

[85]  S. Folstein,et al.  “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician , 1975 .

[86]  Peter Csermely,et al.  Response to Associate Editor , 2016 .

[87]  F. Crawford,et al.  Vasoactive effects of A beta in isolated human cerebrovessels and in a transgenic mouse model of Alzheimer's disease: role of inflammation. , 2003, Neurological research.

[88]  B T Hyman,et al.  beta-site APP cleaving enzyme mRNA expression in APP transgenic mice: anatomical overlap with transgene expression and static levels with aging. , 2001, The American journal of pathology.

[89]  Dawood B. Dudekula,et al.  Verification and initial annotation of the NIA mouse 15K cDNA clone set , 2001, Nature Genetics.

[90]  G C Roman,et al.  Research criteria for subcortical vascular dementia in clinical trials. , 2000, Journal of neural transmission. Supplementum.

[91]  B. Hyman,et al.  Microglial response to amyloid plaques in APPsw transgenic mice. , 1998, The American journal of pathology.

[92]  V. Hachinski.  Multi-infarct dementia: a reappraisal. , 1991, Alzheimer disease and associated disorders.

[93]  J. Blass,et al.  The role of oxidative abnormalities in the pathophysiology of Alzheimer's disease. , 1991, Revue neurologique.